摘要
目的了解Ⅲ期非小细胞肺癌患者LRP、p53的表达与含铂新辅助化疗方案的疗效以及预后之间的关系。方法通过免疫组化方法研究43例Ⅲ期非小细胞肺癌患者化疗前后肺癌标本LRP、p53的表达,并分析上述指标的表达与新辅助化疗疗效以及生存期的关系。结果在化疗前后的成对标本中,化疗前肺癌标本LRP、p53的表达明显低于化疗后；化疗前LRP表达与化疗有效率呈负相关(LRP阳性组化疗有效率40％,LRP阴性组73．91％．P=0．033)；化疗前p53表达与化疗有效率正相关(p53阳性组化疗有效率76．19％,p53阴性组40．91％．P=0．031)。中位生存期化疗前LRP阴性组和阳性组分别为17个月和16个月,p53化疗前阴性组和阳性组分别为18个月和15个月。Cox回归分析结果提示化疗前p53表达(P=0．029)以及淋巴结转移(P=0．014)是生存期的预后因素。结论检测Ⅲ期非小细胞肺癌化疗前LRP和p53表达有助预测含铂方案新辅助化疗的疗效。化疗前p53超表达以及淋巴结转移提示Ⅲ期非小细胞肺癌患者预后不良。
Objective To evaluate the correlationship between the expressions of lung resistance-related protein（LRP） and p53 as well as the response to platinum-based neoadjuvant chemotherapy and prognosis in patients with stage Ⅲ non small cell lung cancer（NSCLC）. Methods Pre- and post-chemotherapy immunohistochemical studies of lung cancer specimens were performed on 43 patients with stageⅢ NSCLC. The data on response rates and survival were analyzed according to the expressions of LRP and p53. Results In paired samples before and after chemotherapy specimens, expressions of LRP and p53 were significantly lower in prechemotherapy samples than those after chemotherapy. LRP expression before chemotherapy significantly correlated inversely with response to chemotherapy（response rates, 40% for LRP-positive and 73.91 % for LRP-negative, P =0. 033）. p53 expression correlated significantly with response to chemotherapy（response rates,76.19 % for p53-positive and 40.91 % for p53negative, P =0. 031）. The median survival time for LRP negative and positive groups were 17 months and 16 months, respectively. The survival time for p53 negative and positive groups were 18 months and 15months,respectively. In Cox regression analysis, prechemotherapy p53 expression（ P = 0. 029） and pathologically positive lymph nodes（ P = 0. 014） were identified as prognostic factors for survival time. Conclusion These findings indicate that expression of LRP and p53 may be useful to predict platinum-based neoadjuvant chemotherapy response in stage Ⅲ NSCLC. Prechemotherapy p53 overexpression and positive lymph nodes may suggest poor prognosis for patients with stageⅢ NSCLC.
出处
《肿瘤》
CAS
CSCD
北大核心
2005年第6期609-612,共4页
Tumor
关键词
癌
非小细胞肺
新辅助化疗
多药抗药相关蛋白质类
预后
蛋白质P53
Carcinoma,non-small cell lung
Neoadjuvant chemotherapy
Muhidrug resistance-associated protein
Prognosis
Protein p53
